Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China
Diabetes · 2024
DOI: 10.2337/db23-0377 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2024. Verfasst von Lixin Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, …. Hauptthemen laut MEDLINE: Diabetic Neuropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Haisco Pharmaceutical Group Co., Ltd..
Abstract (Originalsprache)
Diabetic peripheral neuropathy (DPN) is a highly prevalent chronic complication in type 2 diabetes (T2D) for which no effective treatment is available. In this multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial in China, patients with T2D with DPN received acetyllevocarnitine hydrochloride (ALC; 1,500 mg/day; n = 231) or placebo (n = 227) for 24 weeks, during which antidiabetic therapy was maintained. A significantly greater reduction in modified Toronto clinical neuropathy score (mTCNS) as the primary end point occurred in the ALC group (−6.9 ± 5.3 points) compared with the placebo group (−4.7 ± 5.2 points; P < 0.001). Effect sizes (ALC 1.31 and placebo 0.85) represented a 0.65-fold improvement in ALC treatment efficacy. The mTCNS values for pain did not differ significantly between the two groups (P = 0.066), whereas the remaining 10 components of mTCNS showed significant improvement in the ALC group compared with the placebo group (P < 0.05 for all). Overall results of electrophysiological measurements were inconclusive, with significant improvement in individual measurements limited primarily to the ulnar and median nerves. Incidence of treatment-emergent adverse events was 51.2% in the ALC group, among which urinary tract infection (5.9%) and hyperlipidemia (7.9%) were most frequent. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Endocrinology, Fourth Hospital of Harbin Medical University, Harbin, China.
- Department of Endocrinology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
- Department of Endocrinology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
- Department of Endocrinology, Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng, China.
- Department of Endocrinology, Beijing Pinggu Hospital, Beijing, China.
ORCID-Profile: Lixin Guo
Förderung
- Haisco Pharmaceutical Group Co., Ltd.
Zitieren
APA
Guo, L., Pan, Q., Cheng, Z., Li, Z., Jiang, H., Zhang, F., Li, Y., Qiu, W., Lu, S., Tian, J., Fu, Y., Li, F., & Li, D. (2024). Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. Diabetes. https://doi.org/10.2337/db23-0377
Vancouver
Guo L, Pan Q, Cheng Z, Li Z, Jiang H, Zhang F, et al. Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China. Diabetes. 2024. doi:10.2337/db23-0377
BibTeX
@article{Guo2024,
author = {Guo, Lixin and Pan, Qi and Cheng, Zhifeng and Li, Zhiyong and Jiang, Hongwei and Zhang, Fang and Li, Yufeng and Qiu, Wei and Lu, Song and Tian, Junhang and Fu, Yanqin and Li, Fangqiong and Li, Danqing},
title = {Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0377}
}
EUVIMED